Lexology November 30, 2023
Axinn Veltrop & Harkrider LLP

I’m not saying that anyone from the Biden administration was reading my blog post last week on drug shortages, and maybe it’s just a coincidence that the White House announced new efforts to strengthen supply chains less than a week after my post! But, for the first meeting of the new White House Council on Supply Chain Resilience, the administration announced plans to, among other things, use the Defense Production Act to have more essential medicines made within the United States. In fact, $35 million has been identified by HHS to invest in the domestic production of key starting materials in certain sterile injectables. In addition, HHS is designating a new Supply Chain Resilience and Shortage Coordinator to address shortages...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, HHS, Pharma, Pharma / Biotech, Supply Chain, Technology
Innovation — but at what price? CMMI Under the Microscope
STAT+: Momentum builds for House bill cracking down on Chinese biotechs
Whatever Happened to Biden’s Public Option?
Biden administration punts menthol cigarette rule indefinitely
What the Biden administration’s artificial intelligence executive order means for radiology

Share This Article